Uncategorized

CEO Emmes & PE Board Advisor

Peter is an accomplished drug developer and innovative senior pharmaceutical executive who is currently the CEO of Emmes as well as advising boards, private equity investors, and leaders across the pharmaceutical and biotech industry.  He has extensive global experience across a broad range of therapeutic areas, including oncology, immunology, neuroscience, vaccines, anti-infectives, cardiovascular and retinal gene therapy – from First in Human to Medical Affairs.

In his current role as CEO of Emmes, he is responsible for setting both the strategic direction and the day-to-day operations of the full service CRO operating in 30+ countries and across multiple disease areas including ophthalmology, vaccines, rare disease, cell & gene therapy, and neuroscience.  Emmes is collaborating with more than 210 sponsors, within the pharmaceutical/biotech industry, government, including over a dozen institutes of the National Institutes of Health (NIH), academic organizations, and non‐profit foundations.

Until January 2023, Peter was the Head of Global Development at Janssen R&D where he was responsible for leading the Global Development organization (including statistics, clinical pharmacology, clinical operations, data operations, project and portfolio management, etc.) in support of delivering a broad ranging portfolio of 450+ studies across all therapeutic areas and all phases from PhI -IV. In this role he managed a 10,000+ globally distributed organization and a $2bn+ operating budget to support the design of innovative drug development programs and the implementation of innovative approaches to trial design and execution including trial virtualization, digital health, patient-centered research, and diversity in clinical trials.

Prior to joining Janssen in 2017, Peter was the Senior Vice President of Global Clinical Operations at Bristol Myers-Squibb where he had spent 14 years holding positions of increasing leadership scope in Medical Affairs, Regulatory Operations and R&D Operations.  He also served on the TransCelerate Biopharmaceutical Board of Directors.  Prior to joining BMS, Peter was a consultant with Accenture, focusing on post-merger integration of R&D organizations.  He is a graduate of Nottingham University in the UK and lives in Chester, NJ.

CEO | Co-Founder, Care at Hand (Acq by Mindoula Health)

Dr. Ostrovsky is a practicing physician and social entrepreneur who co-founded Care at Hand. He continues to lead Care at Hand’s executive management and strategic vision since its acquisition by Mindoula Health.

He has led teams at the World Health Organization, United States Senate, and San Francisco Health Department toward health system strengthening through technology. Andrey has contributed to legislation at the city and national level to advance care delivery for vulnerable populations. And he serves on several boards and committees dedicated to interoperability standards, quality improvement, and innovation including the National Quality Forum, Office of the National Coordinator (ONC), and the National Transitions of Care Coalition (NTOCC), among others. He is a published researcher in quality improvement, healthcare innovation, and care coordination.

Andrey holds a Medical Doctorate and undergraduate degrees in Chemistry and Psychology Magna cum Laude, and is a member of Phi Beta Kappa. Andrey completed his pediatrics residency training in the Boston Combined Residency Program at Boston Medical Center and Boston Children’s Hospital where he was a clinical instructor at Harvard Medical School. He is teaching faculty and attending physician at Children’s National Medical Center.

CEO, GlycoMimetics, Inc.

Rachel King is co-founder and CEO of GlycoMimetics, Inc. (GMI), a biotechnology company which has so far raised over $60 million in venture capital financing and recently completed a strategic partnership with Pfizer. Before founding GMI, she was an Executive in Residence at New Enterprise Associates, one of the nation’s leading venture capital firms. Mrs. King came to NEA after serving as a Senior Vice President of Novartis Corporation. Before joining Novartis, Mrs. King spent ten years with Genetic Therapy, Inc. through the company’s early stage, initial public offering, and eventual sale to Novartis. There she held various positions, including as the Company’s CEO. Mrs. King also worked previously at ALZA Corporation in Palo Alto, California and at Bain and Company in Boston. She received her B.A degree from Dartmouth College and her MBA from Harvard Business School. Mrs. King currently serves on the Board of the Biotechnology Industry Association (“BIO”). At BIO, she is Vice Chair of the Health Section Governing Board and is a former Chair of the Emerging Companies Governing Board. She is also a Member of the Maryland Life Sciences Advisory Board appointed by Governor Martin O’Malley and of the Board of Directors of the MDBIO Foundation.

Principal, J. Rosario et Al, LLC

Biomedical entrepreneur, physician, leader, advocate, educator, and biomedical researcher with thirty four consecutive years of experience in strategic clinical research development, effective public-private partnerships, international multidisciplinary collaborations, biomedical education, science administration, and organizational development in the United States and around the world. Superior leadership, organization, management, communication and negotiation skills. Extensive national and international professional network in medicine, biotechnology, government, multilateral organizations, industry, and philanthropy.

CEO, Phlow Corporation – Entrepreneur, Investor, Mentor

Dr. Eric S. Edwards is currently the co-founder and CEO of Phlow Corporation, a leading impact-driven pharmaceutical company focused on securing the supply chain for critical essential medicines and their ingredients in America. Previously, Dr. Edwards was an independent executive healthcare, pharmaceutical, and medical device consultant to small and large multi-national corporations. Prior to consulting, Dr. Edwards was the co-founder of Kaléo, Inc., a pharmaceutical company in Richmond, VA developing novel medicines for the treatment of a variety or chronic and acute-care diseases. He is co-inventor of several currently marketed products, including AUVI-Q, an epinephrine Auto-injector for the treatment of allergic emergencies (anaphylaxis) as well as the Naloxone Auto-injector (Rapid Opioid Countermeasure System) currently being deployed by the DoD in case of an opioid-related attack on the homeland or abroad as a part of the warfighter’s medical arsenal.

Dr. Edwards has over 240 patents and has authored numerous publications in the allergy and opioid use disorder arena as well as on America’s essential medicine supply chain. Dr. Edwards has been active on several committees and boards, including being appointed by the Governor to the Board of the Virginia Biotechnology Research Park Authority/ Activation Capital and serving as a mentor and Board member for Lighthouse Labs, a nationally-recognized, Top 25 Accelerator. He is also on the founding Board of the Food Allergy Science Initiative (FASI) working with world-class researchers to find a cure and develop treatments for food allergies. Dr. Edwards graduated from Virginia Commonwealth University’s guaranteed admission program. While at VCU/MCV, he received a B.S. in Biology, his Ph.D. in the Pharmaceutical Sciences, and M.D. degrees.

Senior Vice President, Global External Affairs – Secretary, USP Convention – Secretary, USP Board of Trustees

Anthony Lakavage is Senior Vice President, Global External Affairs and Secretary, USP Convention and Board of Trustees. In his role, Mr. Lakavage oversees Global Communications, U.S. and International Public Policy and Regulatory Affairs, Global Stakeholder Engagement and the USP Quality Institute. He is the lead architect of the organization’s external engagement strategy and represents USP in a variety of forums involving the U.S. Food and Drug Administration and Congress, international regulatory authorities and ministries of health, professional and trade organizations, non-governmental organizations and the news media.Anthony Lakavage is Senior Vice President, Global External Affairs and Secretary, USP Convention and Board of Trustees. In his role, Mr. Lakavage oversees Global Communications, U.S. and International Public Policy and Regulatory Affairs, Global Stakeholder Engagement and the USP Quality Institute. He is the lead architect of the organization’s external engagement strategy and represents USP in a variety of forums involving the U.S. Food and Drug Administration and Congress, international regulatory authorities and ministries of health, professional and trade organizations, non-governmental organizations and the news media.

As secretary to the USP Convention, Mr. Lakavage works closely with the 450 member organizations comprising the USP Convention, which includes healthcare practitioner and patient organizations, industry associations, and governments. As Secretary to the Board, he supports the Board’s work on organization strategy, and financial and risk management. He is an officer of the USP Convention.As secretary to the USP Convention, Mr. Lakavage works closely with the 450 member organizations comprising the USP Convention, which includes healthcare practitioner and patient organizations, industry associations, and governments. As Secretary to the Board, he supports the Board’s work on organization strategy, and financial and risk management. He is an officer of the USP Convention.

Mr. Lakavage has worked in numerous segments of the life sciences industry including the pharmaceutical, vaccine, medical technology, and clinical laboratory sectors. His experience is geographically diverse and spans the U.S. federal and state level, Europe, global institutions and emerging markets.Mr. Lakavage has worked in numerous segments of the life sciences industry including the pharmaceutical, vaccine, medical technology, and clinical laboratory sectors. His experience is geographically diverse and spans the U.S. federal and state level, Europe, global institutions and emerging markets.

Mr. Lakavage brings more than twenty years of demonstrated leadership in public affairs; public policy and government relations; and global health advocacy to his role at USP. A biopharmaceutical industry veteran, Mr. Lakavage has held a variety of US and international public policy and government affairs leadership roles for GlaxoSmithKline, Gilead Sciences, Chiron Corporation and Applied Biosystems. Prior to joining USP, Mr. Lakavage worked in the medical technology sector serving as Worldwide Vice President, Public Affairs, at Becton Dickinson. Earlier in his career, he worked for Pennsylvania Lt. Gov. Mark Singel and Missouri Congressman Alan Wheat.Mr. Lakavage brings more than twenty years of demonstrated leadership in public affairs; public policy and government relations; and global health advocacy to his role at USP. A biopharmaceutical industry veteran, Mr. Lakavage has held a variety of US and international public policy and government affairs leadership roles for GlaxoSmithKline, Gilead Sciences, Chiron Corporation and Applied Biosystems. Prior to joining USP, Mr. Lakavage worked in the medical technology sector serving as Worldwide Vice President, Public Affairs, at Becton Dickinson. Earlier in his career, he worked for Pennsylvania Lt. Gov. Mark Singel and Missouri Congressman Alan Wheat.

Mr. Lakavage earned his Bachelor of Arts Degree, cum laude, in International Politics from Saint Joseph’s University, and his Juris Doctorate, cum laude, from the Temple University School of Law–where he served on the Temple Political & Civil Rights Law Review staff. He is admitted to the bar in Pennsylvania and New Jersey.Mr. Lakavage earned his Bachelor of Arts Degree, cum laude, in International Politics from Saint Joseph’s University, and his Juris Doctorate, cum laude, from the Temple University School of Law–where he served on the Temple Political & Civil Rights Law Review staff. He is admitted to the bar in Pennsylvania and New Jersey.

LinkedIn

Rich Bendis was a speaker at the BioHealth Capital Region Forum last week to discuss the state of the BioHealth industry in the capital region and benchmark our region against the top regions in the United States.

View Presentation